Literature DB >> 21420060

Comparison of the usefulness of cardiac resynchronization therapy in three age-groups (<65, 65-74 and ≥75 Years) (from the InSync/InSync ICD Italian Registry).

Stefano Fumagalli1, Sergio Valsecchi, Giuseppe Boriani, Maurizio Gasparini, Maurizio Landolina, Maurizio Lunati, Margherita Padeletti, Francesca Tronconi, Niccolò Marchionni, Luigi Padeletti.   

Abstract

Chronic heart failure is one of the most important geriatric syndromes, associated with disability, increased hospital admissions, and high mortality. The aim of this study was to evaluate the existence of age-related differences in clinical effectiveness and outcomes of cardiac resynchronization therapy (CRT), alone or in combination with an implantable cardioverter-defibrillator (CRT-D), in a large, real-world registry. A total of 1,787 patients admitted for CRT or CRT-D to the 117 centers participating in the InSync/InSync ICD Italian Registry from 1999 to 2005 were evaluated. Patients were divided into 3 age groups: <65 years (n = 571), 65 to 74 years (n = 740), and ≥75 years (n = 476). The left ventricular ejection fraction did not differ in the 3 groups (26 ± 8% vs 26 ± 7% vs 27 ± 8%, p = 0.123). Atrial fibrillation prevalence demonstrated an age-related increase. The use of recommended medical therapy for chronic heart failure decreased with age, as well as CRT-D implantation (p <0.001). The percentage of echocardiographic responders to CRT was similar in the 3 groups, and New York Heart Association class significantly improved independent of age. During the follow-up period (19 ± 13 months), all-cause mortality was higher in patients aged ≥75 years than in those aged <65 years (p = 0.005). In the whole population, mortality was associated with the nonresponder condition, the presence of atrial fibrillation and the lack of prescription of recommended medical therapy. In conclusion, CRT improved left ventricular performance and functional capacity independent of age. The proportion of the responder condition to CRT was the same in all groups. Pharmacologic undertreatment is an important issue in a "real-world" geriatric population.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21420060     DOI: 10.1016/j.amjcard.2011.01.031

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

Review 1.  Systolic heart failure in the elderly: optimizing medical management.

Authors:  Jonathan P Man; Bodh I Jugdutt
Journal:  Heart Fail Rev       Date:  2012-09       Impact factor: 4.214

2.  Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials.

Authors:  Paul L Hess; Sana M Al-Khatib; Joo Y Han; Rex Edwards; Gust H Bardy; J Thomas Bigger; Alfred Buxton; Riccardo Cappato; Paul Dorian; Al Hallstrom; Alan H Kadish; Peter J Kudenchuk; Kerry L Lee; Daniel B Mark; Arthur J Moss; Richard Steinman; Lurdes Y T Inoue; Gillian Sanders
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2015-02-10

Review 3.  Clinical, laboratory, and pacing predictors of CRT response.

Authors:  Jagdesh Kandala; Robert K Altman; Mi Young Park; Jagmeet P Singh
Journal:  J Cardiovasc Transl Res       Date:  2012-02-24       Impact factor: 4.132

4.  Impact of diabetes mellitus on the clinical response to cardiac resynchronization therapy in elderly people.

Authors:  Celestino Sardu; Raffaele Marfella; Gaetano Santulli
Journal:  J Cardiovasc Transl Res       Date:  2014-02-06       Impact factor: 4.132

Review 5.  Similarities and differences in patient characteristics between heart failure registries versus clinical trials.

Authors:  Abhinav Sharma; Justin A Ezekowitz
Journal:  Curr Heart Fail Rep       Date:  2013-12

Review 6.  Cardiac Resynchronization Therapy Outcomes in Type 2 Diabetic Patients: Role of MicroRNA Changes.

Authors:  Celestino Sardu; Michelangela Barbieri; Maria Rosaria Rizzo; Pasquale Paolisso; Giuseppe Paolisso; Raffaele Marfella
Journal:  J Diabetes Res       Date:  2015-11-09       Impact factor: 4.011

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.